Viridian Therapeutics, Inc. 1S1.F Stock
Viridian Therapeutics, Inc. Price Chart
Viridian Therapeutics, Inc. 1S1.F Financial and Trading Overview
| Viridian Therapeutics, Inc. stock price | 12.3 EUR |
| Previous Close | 24.2 EUR |
| Open | 25.2 EUR |
| Bid | 25.2 EUR x N/A |
| Ask | 25.8 EUR x N/A |
| Day's Range | 25.2 - 25.2 EUR |
| 52 Week Range | 9.75 - 34.2 EUR |
| Volume | 26 EUR |
| Avg. Volume | 0 EUR |
| Market Cap | 1.16B EUR |
| Beta (5Y Monthly) | 0.984859 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -4.13 EUR |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 35.2 EUR |
1S1.F Valuation Measures
| Enterprise Value | 811.13M EUR |
| Trailing P/E | N/A |
| Forward P/E | -9.509434 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 698.5169 |
| Price/Book (mrq) | 5.031949 |
| Enterprise Value/Revenue | 490.404 |
| Enterprise Value/EBITDA | -4.492 |
Trading Information
Viridian Therapeutics, Inc. Stock Price History
| Beta (5Y Monthly) | 0.984859 |
| 52-Week Change | 145.68% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 34.2 EUR |
| 52 Week Low | 9.75 EUR |
| 50-Day Moving Average | 23.27 EUR |
| 200-Day Moving Average | 24.74 EUR |
1S1.F Share Statistics
| Avg. Volume (3 month) | 0 EUR |
| Avg. Daily Volume (10-Days) | 0 EUR |
| Shares Outstanding | 43.13M |
| Float | 35.26M |
| Short Ratio | N/A |
| % Held by Insiders | 1.90% |
| % Held by Institutions | 97.32% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:15 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -10936.39% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -39.68% |
| Return on Equity (ttm) | -66.64% |
Income Statement
| Revenue (ttm) | 1.65M EUR |
| Revenue Per Share (ttm) | 0.05 EUR |
| Quarterly Revenue Growth (yoy) | -54.60% |
| Gross Profit (ttm) | -99122000 EUR |
| EBITDA | -180568000 EUR |
| Net Income Avi to Common (ttm) | -172332000 EUR |
| Diluted EPS (ttm) | -4.32 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 373.86M EUR |
| Total Cash Per Share (mrq) | 8.67 EUR |
| Total Debt (mrq) | 6.27M EUR |
| Total Debt/Equity (mrq) | 1.79 EUR |
| Current Ratio (mrq) | 12.931 |
| Book Value Per Share (mrq) | 5.008 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -134768992 EUR |
| Levered Free Cash Flow (ttm) | -73191872 EUR |
Profile of Viridian Therapeutics, Inc.
| Country | Germany |
| State | MA |
| City | Waltham |
| Address | 221 Crescent Street |
| ZIP | 02453 |
| Phone | 617 272 4600 |
| Website | https://www.viridiantherapeutics.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 86 |
Viridian Therapeutics, Inc., a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-002 and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED. It also provides VRDN-004, a discovery-stage therapeutic antibody program for rare disease; and VRDN-005 and VRDN-006, a preclinical program for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. is headquartered in Waltham, Massachusetts.
Q&A For Viridian Therapeutics, Inc. Stock
What is a current 1S1.F stock price?
Viridian Therapeutics, Inc. 1S1.F stock price today per share is 12.3 EUR.
How to purchase Viridian Therapeutics, Inc. stock?
You can buy 1S1.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Viridian Therapeutics, Inc.?
The stock symbol or ticker of Viridian Therapeutics, Inc. is 1S1.F.
Which industry does the Viridian Therapeutics, Inc. company belong to?
The Viridian Therapeutics, Inc. industry is Biotechnology.
How many shares does Viridian Therapeutics, Inc. have in circulation?
The max supply of Viridian Therapeutics, Inc. shares is 65.1M.
What is Viridian Therapeutics, Inc. Price to Earnings Ratio (PE Ratio)?
Viridian Therapeutics, Inc. PE Ratio is now.
What was Viridian Therapeutics, Inc. earnings per share over the trailing 12 months (TTM)?
Viridian Therapeutics, Inc. EPS is -4.13 EUR over the trailing 12 months.
Which sector does the Viridian Therapeutics, Inc. company belong to?
The Viridian Therapeutics, Inc. sector is Healthcare.